Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317620

SCHEMBL25317620

SCHEMBL25317620

CC(C)(C)OC(=O)N1CCC2(CC1)C(=O)N(COCC[Si](C)(C)C)c1ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DDR1 Q08345 1/20 0.41
▸ BACE1 P56817 6/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ PKM P14618 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ ALK Q9UM73 1/20 0.36
▸ NAMPT P43490 2/20 0.36
▸ JAK2 O60674 2/20 0.36
▸ JAK1 P23458 2/20 0.36
▸ TACR1 P25103 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506793 1.00 DDR1 (0.41) DDR1BACE1KMT2AMEN1PKM
SCHEMBL30506821 0.90 ESR2 (0.39) BACE1PKMNAMPTJAK2JAK1
SCHEMBL25315913 0.90 ESR2 (0.39) BACE1PKMNAMPTJAK2JAK1
SCHEMBL31436447 0.90 DDR1 (0.41) DDR1KMT2AMEN1SMN1; SMN2NAMPT
SCHEMBL25317240 0.86 TACR1 (0.35) BACE1ALKNAMPTTACR1
SCHEMBL30507038 0.86 TACR1 (0.35) BACE1ALKNAMPTTACR1
SCHEMBL15699763 0.85 NAMPT (0.37) DDR1KMT2AMEN1PKMALK
SCHEMBL25315612 0.85 PRMT5 (0.42) BACE1PKMNAMPTTACR1
SCHEMBL17586454 0.79 IP6K1 (0.47) BACE1ALDH1A1
SCHEMBL31758740 0.79 IP6K1 (0.47) BACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR DDR1 4426/4885BACE1 35/4885KMT2A 4715/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 DDR1 4428/4885BACE1 30/4885KMT2A 4701/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR DDR1 4426/4885BACE1 35/4885KMT2A 4715/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 DDR1 4428/4885BACE1 30/4885KMT2A 4701/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 DDR1 4428/4885BACE1 30/4885KMT2A 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.